Lopez, Andrea
Reyna, Denis E.
Gitego, Nadege
Kopp, Felix
Zhou, Hua
Miranda-Roman, Miguel A.
Nordstrøm, Lars Ulrik
Narayanagari, Swathi-Rao
Chi, Ping
Vilar, Eduardo http://orcid.org/0000-0001-6404-3761
Tsirigos, Aristotelis http://orcid.org/0000-0002-7512-8477
Gavathiotis, Evripidis http://orcid.org/0000-0001-6319-8331
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (2R01CA178394, F31CA236434)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (1S10OD01630)
New York State Stem Cell Science (C029154)
Pershing Square Sohn Cancer Research Alliance, Irma T. Hirschl Trust
Article History
Received: 11 October 2020
Accepted: 9 February 2022
First Online: 7 March 2022
Competing interests
: E.G., D.E.R., F.K. are inventors on patent applications regarding small molecule BAX activators submitted by Albert Einstein College of Medicine. These patent applications are licensed to BAKX Therapeutics. E.G. is a co-founder and scientific advisor of BAKX Therapeutics, Stelexis Therapeutics, and Selphagy Therapeutics now part of Life Biosciences. E. Vilar has a consulting and advisory role with Janssen Research and Development. None of the above companies have sponsored this research. No potential conflicts of interest were disclosed by the other authors.